Validity of serum CA125, HE4 and risk of ovarian malignancy algorithm in (ROMA) in the prediction of ovarian cancer

Abstract

A cross-sectional descriptive study on 65 ovarian tumors patients hospitalized at Thai Nguyen Hospital A from Jan 2020 to June 2021 to identify on the value of HE4, CA125 and ROMA in the prediction of avarian cancer. The results showed that there were 12 cases of ovarian cancer and 53 patients with benign ovarian tumors. Median values of CA 125, HE4, and ROMA of ovarian cancer were 378.8U/ml; 350.8 pmol/l; 90.1% higher than benign ovarian (p < 0.01). Pre-menopausal, the sensitivities and specificity associated with the ability of CA125, HE4, ROMA, to distinguish between malignant versus benign ovarian masses were 40% and 66.7%; 80% and 100%; 100% and 95.8% respectively. Post-menopausal, the sensitivities and specificity associated with the ability of CA125, HE4, ROMA, to distinguish between malignant versus benign ovarian masses were 100% and 100%; 85.7% and 100%; 100% and 100% respectively. Areas under the ROC curve of CA-125, HE4, ROMA were 0.874; 0.997 and 0.995 respectively. Conclusion: All three of CA 125, HE4, and ROMA have good validity in the diagnosis of ovarian cancer. CA125, HE4, ROMA should be widely applied in clinical practice to help assess, manage and predict patients with suspected ovarian cancer.